296 related articles for article (PubMed ID: 17379663)
1. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.
Heidel JD; Yu Z; Liu JY; Rele SM; Liang Y; Zeidan RK; Kornbrust DJ; Davis ME
Proc Natl Acad Sci U S A; 2007 Apr; 104(14):5715-21. PubMed ID: 17379663
[TBL] [Abstract][Full Text] [Related]
2. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.
Davis ME
Mol Pharm; 2009; 6(3):659-68. PubMed ID: 19267452
[TBL] [Abstract][Full Text] [Related]
3. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.
Bartlett DW; Davis ME
Bioconjug Chem; 2007; 18(2):456-68. PubMed ID: 17326672
[TBL] [Abstract][Full Text] [Related]
5. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles.
Bartlett DW; Davis ME
Biotechnol Bioeng; 2008 Mar; 99(4):975-85. PubMed ID: 17929316
[TBL] [Abstract][Full Text] [Related]
6. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
7. pH-triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo.
Kolli S; Wong SP; Harbottle R; Johnston B; Thanou M; Miller AD
Bioconjug Chem; 2013 Mar; 24(3):314-32. PubMed ID: 23305315
[TBL] [Abstract][Full Text] [Related]
8. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
Davis ME; Zuckerman JE; Choi CH; Seligson D; Tolcher A; Alabi CA; Yen Y; Heidel JD; Ribas A
Nature; 2010 Apr; 464(7291):1067-70. PubMed ID: 20305636
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
10. Proteinase K-containing lipid nanoparticles for therapeutic delivery of siRNA LOR-1284.
Kim DC; Cho YA; Li H; Yung BC; Lee RJ
Anticancer Res; 2014 Jul; 34(7):3531-5. PubMed ID: 24982365
[TBL] [Abstract][Full Text] [Related]
11. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
12. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.
Wang XL; Xu R; Lu ZR
J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104
[TBL] [Abstract][Full Text] [Related]
13. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
Guo J; Cheng WP; Gu J; Ding C; Qu X; Yang Z; O'Driscoll C
Eur J Pharm Sci; 2012 Apr; 45(5):521-32. PubMed ID: 22186295
[TBL] [Abstract][Full Text] [Related]
14. Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy.
Hallaj-Nezhadi S; Lotfipour F; Dass CR
Pharmazie; 2010 Dec; 65(12):855-9. PubMed ID: 21284252
[TBL] [Abstract][Full Text] [Related]
15. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
[TBL] [Abstract][Full Text] [Related]
16. Different mechanisms for nanoparticle formation between pDNA and siRNA using polyrotaxane as the polycation.
Yamada Y; Hashida M; Nomura T; Harashima H; Yamasaki Y; Kataoka K; Yamashita A; Katoono R; Yui N
Chemphyschem; 2012 Apr; 13(5):1161-5. PubMed ID: 22383277
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
[TBL] [Abstract][Full Text] [Related]
18. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma.
Hu-Lieskovan S; Heidel JD; Bartlett DW; Davis ME; Triche TJ
Cancer Res; 2005 Oct; 65(19):8984-92. PubMed ID: 16204072
[TBL] [Abstract][Full Text] [Related]
19. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles.
Carmona S; Jorgensen MR; Kolli S; Crowther C; Salazar FH; Marion PL; Fujino M; Natori Y; Thanou M; Arbuthnot P; Miller AD
Mol Pharm; 2009; 6(3):706-17. PubMed ID: 19159285
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical characterization techniques for lipid based delivery systems for siRNA.
Kapoor M; Burgess DJ; Patil SD
Int J Pharm; 2012 May; 427(1):35-57. PubMed ID: 21979250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
